abstract |
The present invention is substituted with a novel hexafluoroisopropanol of formula (I), wherein R 1 to R 4 , X, m, and n are as defined in the description and claims. It relates to cyclohexane derivatives, and physiologically acceptable salts and esters thereof. These compounds bind to LXRα and LXRβ and can be used as pharmaceuticals. |